• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»behavioral health

What Saban Community Clinic’s Crenshaw project reveals about urban healthcare deserts

By Pallavi Madhiraju on May 10, 2026   Pharma & Biotech  

What Saban Community Clinic’s Crenshaw project reveals about urban healthcare deserts

South Los Angeles lacks reliable primary care. Saban Community Clinic’s Crenshaw center tests whether integrated care can close that gap.

Why the Syra Health and Nora Mental Health deal matters for telebehavioral care in Indiana

By Pallavi Madhiraju on April 3, 2026   Pharma & Biotech  

Why the Syra Health and Nora Mental Health deal matters for telebehavioral care in Indiana

Syra Health and Nora Mental Health are linking AI triage with teletherapy in Indiana. Read why this could reshape digital mental health access.

Can online therapy finally close New Mexico’s mental health gap? SkyMD bets big on statewide virtual care

By Pallavi Madhiraju on February 13, 2026   Pharma & Biotech  

Can online therapy finally close New Mexico’s mental health gap? SkyMD bets big on statewide virtual care

SkyMD launches statewide online therapy in New Mexico. Find out what this expansion means for access, regulation, and teletherapy adoption.

Brello Rise enters the obesity care landscape as a digital wellness adjunct to medical weight loss

By Pallavi Madhiraju on January 26, 2026   Pharma & Biotech  

Brello Rise enters the obesity care landscape as a digital wellness adjunct to medical weight loss

Brello Health launches Brello Rise, a digital studio for patients in medical weight loss programs. Find out what this signals for obesity care models.

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes